Michael P. Scheid

Degrees
BSc University of Guelph, Canada
PhD University of British Columbia, Canada.
Current position
Professor of Biology, York University, Toronto, Canada.

Appointments
Chair, Cancer Research Society, Canada
Cancer Biology and Therapeutics, Canadian Institutes of Health Research, Committee Member, New Investigator Awardee, Canadian Institutes of Health Research.
Chair, Advisory Committee on Biological Safety, York University

Consulting experience
Consultant, Gilberts LLP, Patent and Trademark Law (Toronto)
Cell Signaling Technologies (Boston)

Biography
Michael Scheid is a molecular biologist focused on cell signaling pathways that influence cancer initiation and progression. His work on the lipid kinase PI3K and AKT led to a number of highly cited articles and have contributed to the design and development of new cancer treatment therapies. As more clinical trials demonstrating the efficacy of targeted cancer therapies emerge, it is becoming clear that some of the most hopeful treatments are now within our reach. Cancer still has the advantage, however, and current thought is that combinatorial drug therapies that converge treatment modalities will provide superior efficacy. As a specialist in understanding how kinases function, Dr. Scheid is positioned to identify and exploit these signaling enzymes. He is Chairman of Cancer Research Society of Canada grant review committee. He also has consulting experience in science field with one of the biggest suppliers of reagents worldwide (Cell Signaling Technologies) and in legal spheres (Gilberts LLP, Patent and Trademark Law).